Executive Committee: Vaxcyte, Inc.

Manager
Positions heldSince
Grant Pickering

Grant Pickering

56 year

Chief Executive Officer 27/05/2013
Founder 27/05/2013
Whitney Jones

Whitney Jones

Human Resources Officer 16/01/2024
Jakub Simon

Jakub Simon

Chief Tech/Sci/R&D Officer 11/10/2022
Mikhail Eydelman

Mikhail Eydelman

43 year

Compliance Officer 01/04/2022
General Counsel 01/04/2022
Corporate Secretary 01/03/2023
Janet Graesser

Janet Graesser

Investor Relations Contact 01/04/2021
Public Communications Contact 01/04/2021
Andrew Guggenhime

Andrew Guggenhime

55 year

Director of Finance/CFO 01/05/2020
President 01/01/2021
James Wassil

James Wassil

54 year

Chief Operating Officer 01/12/2019

Composition of the Board of Directors: Vaxcyte, Inc.

Director
CommitteesSince
Carlos Paya

Carlos Paya

65 year

Chairman 27/10/2021
Independent Dir/Board Member 27/10/2021
K. Hirth

K. Hirth

72 year

Governance Committee 01/09/2016
Nominating Committee 01/09/2016
Compensation Committee 01/08/2018
Audit Committee
Halley Gilbert

Halley Gilbert

54 year

Audit Committee 01/04/2020
Governance Committee Chair 01/04/2020
Nominating Committee Chair 01/04/2020
Anne Drapeau

Anne Drapeau

57 year

Governance Committee 16/09/2021
Nominating Committee 16/09/2021
Compensation Committee Chair 16/09/2021
John Furey

John Furey

59 year

Audit Committee 29/05/2020
Compensation Committee 02/07/2024
Grant Pickering

Grant Pickering

56 year

Audit Committee 18/05/2023
Compensation Committee
Heath Lukatch

Heath Lukatch

56 year

Compensation Committee 01/05/2018
Teri Loxam

Teri Loxam

52 year

Audit Committee Chair 19/05/2022
Jacks Lee

Jacks Lee

60 year

Audit Committee 27/11/2023

Former Officers and Directors: Vaxcyte, Inc.

Insider
Positions held
SinceUntil
Karen Alderete
Karen Alderete
Human Resources Officer - 16/01/2024
Michael Kamarck
Michael Kamarck
Director/Board Member 27/10/2021 30/06/2023
Independent Dir/Board Member 27/10/2021 30/06/2023
Kurt von Emster
Kurt von Emster
Director/Board Member 27/10/2021 01/06/2022
Chairman 24/03/2021 27/10/2021
Independent Dir/Board Member 01/07/2015 01/06/2022
Suzanna Fekete
Suzanna Fekete
General Counsel 01/10/2020 01/05/2022
Jane Wright-Mitchell
Jane Wright-Mitchell
Compliance Officer 01/06/2020 01/10/2021
General Counsel 01/01/2019 01/10/2021
Corporate Secretary 01/12/2019 01/10/2021
Patrick Heron
Patrick Heron
Director/Board Member 01/03/2017 16/09/2021
Independent Dir/Board Member 01/03/2017 16/09/2021
Robert Hopfner
Robert Hopfner
Director/Board Member 01/12/2017 16/09/2021
Independent Dir/Board Member 01/12/2017 16/09/2021
William Newell
William Newell
Director/Board Member 01/11/2013 02/06/2021
Independent Dir/Board Member 01/11/2013 02/06/2021
Moncef Slaoui
Moncef Slaoui
Director/Board Member 19/07/2017 01/05/2018
Chairman 01/05/2018 24/03/2021
Independent Dir/Board Member 19/07/2017 24/03/2021
Romulo Colindres
Romulo Colindres
Chief Tech/Sci/R&D Officer 12/11/2020 -
Patrick Enright
Patrick Enright
Director/Board Member 01/07/2015 01/01/2020
Independent Dir/Board Member 01/07/2015 01/01/2020
Elaine Sun
Elaine Sun
Director of Finance/CFO 01/01/2017 01/12/2019
Ashish Khanna
Ashish Khanna
Founder 27/05/2013 -
Corporate Officer/Principal 27/05/2013 -
Tracy Saxton
Tracy Saxton
Director/Board Member - -

Age distribution of managers

Parity Men Women

Male 14
Female 6

Of which Executive Committee

Male 5
Female 2

Of which Directors

Male 6
Female 3
ESG Refinitiv
C-

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy
Logo Vaxcyte, Inc.
Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company’s next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.
Employees
254
More about the company

Departures of Key Persons

Moncef Slaoui
-
Moncef Slaoui

Chairman

01/05/2018 24/03/2021

Kurt von Emster
-
Kurt von Emster

Chairman

24/03/2021 27/10/2021

-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities. Last hours!
BENEFIT NOW